BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16079000)

  • 1. Invasive breast cancer following bilateral subcutaneous mastectomy in a BRCA2 mutation carrier: a case report and review of the literature.
    Kasprzak L; Mesurolle B; Tremblay F; Galvez M; Halwani F; Foulkes WD
    World J Surg Oncol; 2005 Aug; 3():52. PubMed ID: 16079000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preventive surgical prcedures for inherited risk of breast cancer].
    Menke-Pluymers MB; Seynaeve C; van Geel AN; Klijn JG; Meijers-Heijboer EJ; Eggermont AM
    Ned Tijdschr Geneeskd; 2005 Nov; 149(48):2663-7. PubMed ID: 16358615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
    Fatouros M; Baltoyiannis G; Roukos DH
    Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
    Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
    Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.
    Eisen A; Lubinski J; Klijn J; Moller P; Lynch HT; Offit K; Weber B; Rebbeck T; Neuhausen SL; Ghadirian P; Foulkes WD; Gershoni-Baruch R; Friedman E; Rennert G; Wagner T; Isaacs C; Kim-Sing C; Ainsworth P; Sun P; Narod SA
    J Clin Oncol; 2005 Oct; 23(30):7491-6. PubMed ID: 16234515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening and follow-up of the patient at high risk for breast cancer.
    Willey SC; Cocilovo C
    Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerous high-risk epithelial lesions in familial breast cancer.
    Hoogerbrugge N; Bult P; Bonenkamp JJ; Ligtenberg MJ; Kiemeney LA; de Hullu JA; Boetes C; Niermeijer MF; Brunner HG
    Eur J Cancer; 2006 Oct; 42(15):2492-8. PubMed ID: 16908132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A survey of preventive measures among BRCA1 mutation carriers from Poland.
    Gronwald J; Byrski T; Huzarski T; Cybulski C; Stawicka M; Szwiec M; Debniak T; Tulman A; Sun P; Oszurek O; Lubinski J; Narod SA
    Clin Genet; 2007 Feb; 71(2):153-7. PubMed ID: 17250664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation.
    Hermsen BB; Verheijen RH; Menko FH; Gille JJ; van Uffelen K; Blankenstein MA; Meijer S; van Diest PJ; Kenemans P; von Mensdorff-Pouilly S
    Eur J Cancer; 2007 Jul; 43(10):1556-63. PubMed ID: 17532207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.